Tricuspid atresia natural history, complications and prognosis: Difference between revisions
No edit summary |
|||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Template:Tricuspid atresia}} | {{Template:Tricuspid atresia}} | ||
{{CMG}} '''Associate Editor-In-Chief:''' [[User:KeriShafer|Keri Shafer, M.D.]] [mailto:kshafer@bidmc.harvard.edu] [[Priyamvada Singh|Priyamvada Singh, MBBS]] [mailto:psingh13579@gmail.com] '''Assistant Editor-In-Chief:''' [[Kristin Feeney|Kristin Feeney, B.S.]] [mailto:kfeeney@elon.edu] | {{CMG}} '''Associate Editor-In-Chief:'''{{Sara.Zand}} [[User:KeriShafer|Keri Shafer, M.D.]] [mailto:kshafer@bidmc.harvard.edu] [[Priyamvada Singh|Priyamvada Singh, MBBS]] [mailto:psingh13579@gmail.com] '''Assistant Editor-In-Chief:''' [[Kristin Feeney|Kristin Feeney, B.S.]] [mailto:kfeeney@elon.edu] | ||
Revision as of 14:22, 24 August 2020
Tricuspid atresia Microchapters |
Diagnosis |
---|
Treatment |
Special Scenarios |
Case Studies |
Tricuspid atresia natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Tricuspid atresia natural history, complications and prognosis |
FDA on Tricuspid atresia natural history, complications and prognosis |
CDC on Tricuspid atresia natural history, complications and prognosis |
Tricuspid atresia natural history, complications and prognosis in the news |
Blogs on Tricuspid atresia natural history, complications and prognosis |
Risk calculators and risk factors for Tricuspid atresia natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor-In-Chief:Sara Zand, M.D.[2] Keri Shafer, M.D. [3] Priyamvada Singh, MBBS [4] Assistant Editor-In-Chief: Kristin Feeney, B.S. [5]
Natural History, Complications and Prognosis
- Early clinical features in infants includecyanosis of lips and tongue, difficulty in breathing, tiring easily during feeding.
- The severity of cyanosis ininfants with pulmonary stenosis is dependent on the amount ofpulmonary blood flow passing throughpatent ductus arteriosus.
- After physiologic closure of patent ductus arteriosus (PDA), thecyanosis will be aggravated.
- In patients with normalpulmonary blood flow, complications ofheart failure may occur.
- Prognosis is generally poor without surgery and 90% of patients will die before 10 years old.
- The 15-year survival of patients with Fontan procedure is approximately %92 according to Merry et al.
Natural History, Complications, and Prognosis
Natural History
Complications
- Irregular, fast heart rhythms (arrhythmias)
- Chronic diarrhea (from a disease called protein losing enteropathy)
- Heart failure
- Fluid in the abdomen (ascites) and in the lungs (pleural effusion)
- Blockage of the artificial shunt
- Strokes and other neurological complications
- Sudden death
Prognosis
- The prognosis is poor in untreated patients.[1]
References
- ↑ Rao PS (2000). "Tricuspid Atresia". Curr Treat Options Cardiovasc Med. 2 (6): 507–520. doi:10.1007/s11936-000-0046-6. PMID 11096554.